Canada · Delayed Price · Currency is CAD Optimind Pharma Statistics
Total Valuation
Optimind Pharma has a market cap or net worth of CAD 515,742. The enterprise value is 530,092.
| Market Cap | 515,742 |
| Enterprise Value | 530,092 |
Important Dates
The last earnings date was Thursday, October 30, 2025.
| Earnings Date | Oct 30, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Optimind Pharma has 103.15 million shares outstanding. The number of shares has increased by 3.99% in one year.
| Current Share Class | 103.15M |
| Shares Outstanding | 103.15M |
| Shares Change (YoY) | +3.99% |
| Shares Change (QoQ) | -4.72% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.74 |
| PB Ratio | -7.44 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.47 |
| EV / Sales | 3.84 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.58
| Current Ratio | 0.58 |
| Quick Ratio | 0.58 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -28.22% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 151.49% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.59 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 0.16 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.01 |
| Relative Strength Index (RSI) | 42.08 |
| Average Volume (20 Days) | 3,214 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Optimind Pharma had revenue of CAD 138,024 and -118,605 in losses. Loss per share was -0.00.
| Revenue | 138,024 |
| Gross Profit | 90,061 |
| Operating Income | -105,019 |
| Pretax Income | -118,605 |
| Net Income | -118,605 |
| EBITDA | n/a |
| EBIT | -105,019 |
| Loss Per Share | -0.00 |
Balance Sheet
The company has 106,289 in cash and 120,637 in debt, giving a net cash position of -14,348 or -0.00 per share.
| Cash & Cash Equivalents | 106,289 |
| Total Debt | 120,637 |
| Net Cash | -14,348 |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | -69,323 |
| Book Value Per Share | -0.00 |
| Working Capital | -119,323 |
Cash Flow
| Operating Cash Flow | -309,812 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 65.25%, with operating and profit margins of -76.09% and -85.93%.
| Gross Margin | 65.25% |
| Operating Margin | -76.09% |
| Pretax Margin | -85.93% |
| Profit Margin | -85.93% |
| EBITDA Margin | n/a |
| EBIT Margin | -76.09% |
| FCF Margin | n/a |
Dividends & Yields
Optimind Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.99% |
| Shareholder Yield | -3.99% |
| Earnings Yield | -23.00% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Optimind Pharma has an Altman Z-Score of -32.74 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -32.74 |
| Piotroski F-Score | 3 |